Fol. Biol. 2014, 60, 213-219

https://doi.org/10.14712/fb2014060050213

SKOV-3 and Me45 Cell Response to Cisplatin-Based Chemotherapy: an in Vitro Study

A. Gonera1, J. Wawryka1, A. Sobkowicz1, K. Biezunska-Kusiak2, M. Dubinska-Magiera3, A. Krajewski4, Anna Choromańska2

1Faculty of Medicine, Student Scientific Circle of the Wroclaw Medical University, Wroclaw, Poland
2Department of Medical Biochemistry, Wroclaw Medical University, Wroclaw, Poland
3Department of Animal Developmental Biology, University of Wroclaw, Wroclaw, Poland
4Second Department and Clinic of General and Oncological Surgery, Wroclaw Medical University, Wroclaw, Poland

Received January 2014
Accepted June 2014

References

1. Avery-Kiejda, A. K., Bowden, N. A., Croft, A. J., Scurr, L. L., Kairupan, C. F., Ashton, K. A., Talseth-Palmer, B. A., Rizos, H., Zhang, X. D., Scott, R. J., Hersey, P. (2011) P53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation. BMC Cancer 11, 203-219. <https://doi.org/10.1186/1471-2407-11-203>
2. Bai, L., Zhu, W.-G. (2004) p53: structure, function and therapeutic applications. J. Cancer Mol. 4, 141-153.
3. Benathan, M., Alvero-Jackson, H., Mooy, A. M., Scaletta, C., Frenk, E. (1992) Relationship between melanogenesis, glutathione levels and melphalan toxicity in human melanoma cells. Melanoma Res. 2, 305-314. <https://doi.org/10.1097/00008390-199212000-00003>
4. Czernek, U., Tomczyk, D., Dębska, S., Płużańska A. (2009) Chemotherapy of recurrent ovarian cancer. Onkol. Pol. 12, 27-30. (in Polish)
5. Faran, G., Dworakowska, D., Jassem, E. (2004) Clinical value of immunohistochemical assessment of expression of p53, Bcl-2 and Bax proteins in non small cell lung cancer. Contemp. Oncol. 8, 328-337.
6. Garrido, C., Brunet, M., Didelot, C., Zermati, Y., Schmitt, E., Kroemer, G. (2006) Heat shock proteins 27 and 70: antiapoptotic proteins with tumorigenic properties. Cell Cycle 22, 2592-2601. <https://doi.org/10.4161/cc.5.22.3448>
7. Godwin, A. K., Meister, A., O’Dwyer, P. J., Huang, C. S., Hamilton, T. C. Anderson, M. E. (1992) High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc. Natl. Acad. Sci. USA 89, 3070-3074. <https://doi.org/10.1073/pnas.89.7.3070>
8. Gong, J., Zhang, Y., Durfee, J., Weng, D., Liu, C., Koido, S., Song, B., Apostolopoulos, V., Calderwood, S. K. (2010) An HSP70-based vaccine with enhanced immunogenicity for clinical use. J. Immunol. 184, 488-496. <https://doi.org/10.4049/jimmunol.0902255>
9. Green, J. A., Robertson, L. J., Clark, A. H. (1993) Glutathione S-transferase expression in benign and malignant ovarian tumours. Br. J. Cancer 68, 235-239. <https://doi.org/10.1038/bjc.1993.321>
10. Gurtowska, N., Kloskowski, T. (2009) The mechanisms of action of platinum compounds in people with malignant melanoma. Med. Biol. Sci. 23, 11-18.
11. Helmbach, H., Rossmann, E., Kern, M. A., Schadendorf, D. (2001) Drug-resistance in human melanoma. Int. J. Cancer 93, 617-622. <https://doi.org/10.1002/ijc.1378>
12. Hendrickson, A. E., Oberg, A. L., Glaser, G., Camoriano, J. K., Peethambaram, P. P., Colon-Otero, G., Erlichman, C., Ivy, S. P., Kaufmann, S. H., Karnitz, L. M., Haluska, P. (2012) A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma. Gynecol. Oncol. 124, 210-215. <https://doi.org/10.1016/j.ygyno.2011.10.002>
13. Hollstein, M., Rice, K., Greenblatt, M. S., Soussi, T., Fuchs, R., Sørlie, T., Hovig, E., Smith-Sørensen, B., Montesano, R., Harris, C. C. (1994) Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res. 22, 3551-3555.
14. Hu, L., Hofmann, J., Lu, Y., Mills, G. B., Jaffe, R. B. (2002) Inhibition of phosphatidylinositol 3’-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res. 62, 1087-1092.
15. Iersel, M. L. (1996) Inhibition of glutathione S-transferase activity in human melanoma cells by α,β-unsaturated carbonyl derivatives. Effects of acrolein, cinnamaldehyde, citral, crotonaldehyde, curcumin, ethacrynic acid, and trans- 2-hexenal. Chem. Biol. Interact 102, 117-132. <https://doi.org/10.1016/S0009-2797(96)03739-8>
16. Kaźmierczuk, A., Kiliańska, Z. M. (2010) Role of heat shock proteins in cell apoptosis. Adv. Hyg. Exp. Med. 64, 273-283.
17. Kichina, J. V., Rauth, S., Gupta, T., Gudkov, A. V. (2003) Melanoma cells can tolerate high levels of transcriptionally active endogenous p53 but are sensitive to retrovirus-transduced p53. Oncogene 22, 4911-4917. <https://doi.org/10.1038/sj.onc.1206741>
18. Kolwijck, E., Zusterzeel, P. L., Roelofs, H. M., Hendriks, J. C., Peters, W. H., Massuger, L. F. (2009) GSTP1-1 in ovarian cyst fluid and disease outcome of patients with ovarian cancer. Cancer Epidemiol. Biomarkers Prev. 18, 2176-81. <https://doi.org/10.1158/1055-9965.EPI-09-0098>
19. Kulbacka, J., Saczko, J., Chwiłkowska, A. (2008) Colorectal cancer – characteristic and treatment resistance. Oncol. Pract. Clin. 4, 135-140. (in Polish)
20. Li, G., Bush, J. A., Ho, V. C. (2000) p53-dependent apoptosis in melanoma cells after treatment with camptothecin. J. Invest. Dermatol. 114, 514-519. <https://doi.org/10.1046/j.1523-1747.2000.00867.x>
21. Lu, D., Shi, H. C., Wang, Z. X., Gu, X. W., Zeng, Y. J. (2011) Multidrug resistance-associated biomarkers PGP, GST-π, Topo-II and LRP as prognostic factors in primary ovarian carcinoma. Br. J. Biomed. Sci. 68, 69-74. <https://doi.org/10.1080/09674845.2011.11730326>
22. Mackiewicz, J., Kwinta, Ł. (2010) New targeted therapies in the treatment of patients with metastatic melanoma. Contemp. Oncol. 14, 15-22.
23. McIlwain, C. C., Townsend, D. M., Tew, K. D. (2006) Glutathione S-transferase polymorphisms: cancer incidence and therapy. Oncogene 25, 1639-1648. <https://doi.org/10.1038/sj.onc.1209373>
24. Miedzińska-Maciejewska, M., Bodnar, L. (2004) The modulation of multidrug resistance in ovarian cancer patients. Contemp. Oncol. 9, 457-465.
25. Milner, B. J., Allan, L. A., Eccles, D. M., Kitchener, H. C., Leonard, R. C., Kelly, K. F., Parkin, D. E., Haites, N. E. (1993) p53 mutation is a common genetic event in ovarian carcinoma. Cancer Res. 53, 2128-2132.
26. Moral, A., Palou, J., Lafuente, A., Molina, R., Piulachs, J., Castel, T., Trias, M. (1997) Immunohistochemical study of α, μ and π class glutathione S transferase expression in malignant melanoma. Br. J. Dermatol. 136, 345-350. <https://doi.org/10.1046/j.1365-2133.1997.d01-1197.x>
27. Murphy, D., McGown, A. T., Hall, A., Cattan, A., Crowther, D., Fox, B. W. (1992) Glutathione S-transferase activity and isoenzyme distribution in ovarian tumour biopsies taken before or after cytotoxic chemotherapy. Br. J. Cancer 66, 937-942. <https://doi.org/10.1038/bjc.1992.389>
28. Musiał, K., Zwolińska, D. (2010) Heat shock proteins in chronic kidney disease: protectors or aggressors? Nephrol. Dial. Pol. 14, 206-210.
29. Pawlicki, M., Ziobro, M. (2001) The advances in melanoma treatment. Contemp. Oncol. 6, 260-265.
30. Schadendorf, D., Jurgovsky, K., Kohlmus, C. M., Czarnetzki, B. M. (1995) Glutathione and related enzymes in tumor progression and metastases of human melanoma. J. Invest. Dermatol. 105, 109-112. <https://doi.org/10.1111/1523-1747.ep12313403>
31. Saenz-Santamaria, M. C., McNutt, N. S., Bogdany, J. K., Shea, C. R. (1995) p53 expression is rare in cutaneous melanomas. Am. J. Dermatopathol. 17, 344-349. <https://doi.org/10.1097/00000372-199508000-00007>
32. Shiga, H., Heath, E. I., Rasmussen, A. A., Trock, B., Johnston, P. G., Forastiere, A. A., Langmacher, M., Baylor, A., Lee, M., Cullen, K. J. (1999) Prognostic value of p53, glutathione S-transferase π, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer. Clin. Cancer Res. 12, 4097-4104.
33. Siddik, Z. H. (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 47, 7265-7279. <https://doi.org/10.1038/sj.onc.1206933>
34. Silvestrini, R., Daidone, M. G., Veneroni, S., Benini, E., Scarfone, G., Zanaboni, F., Villa, A., Presti, M., Danese, S., Bolis, G. (1998) The clinical predictivity of biomarkers of stage III-IV epithelial ovarian cancer in a prospective randomized treatment protocol. Cancer 82, 159-167. <https://doi.org/10.1002/(SICI)1097-0142(19980101)82:1<159::AID-CNCR20>3.0.CO;2-0>
35. Sirotkin, A. V., Bauer, M. (2011) Heat shock proteins in porcine ovary: synthesis, accumulation and regulation by stress and hormones. Cell Stress Chaperones 16, 379-387. <https://doi.org/10.1007/s12192-010-0252-4>
36. Skórzewska, M., Stępak, E., Polkowski, W. P. (2011) Current status and perspectives of treatment of disseminated melanoma. J. Oncol. 61, 367-379.
37. Slonchak, A., Chwieduk, A., Rzeszowska-Wolny, J., Obolenskaya, M. (2011) Regulation of the glutathione S-transferase P1 expression in melanoma cells. In: Breakthroughs in Melanoma Research, ed. Y. Tanaka, pp. 145-156, InTech, Vienna, Austria.
38. Stępień, A., Izdebska, M., Grzanka, A. (2007) The types of cell death. Hyg. Exp. Med. 61, 420-428.
39. Sznarkowska, A., Olszewski, R., Zawacka-Pankau, J. (2010) Pharmacological activation of tumor suppressor, wild-type p53 as a promising strategy to fight cancer. Hyg. Exp. Med. 64, 396-407.
40. Wrigley, E. C., McGown, A. T., Buckley, H., Hall, A., Crowther D. (1996) Glutathione-S-transferase activity and isoenzyme levels measured by two methods in ovarian cancer, and their value as markers of disease outcome. Br. J. Cancer 73, 763-769. <https://doi.org/10.1038/bjc.1996.133>
41. van der Zee, A. G., van Ommen, B., Meijer, C., Hollema, H., van Bladeren, P. J., de Vries, E. G. (1992) Glutathione S-transferase activity and isoenzyme composition in benign ovarian tumours, untreated malignant ovarian tumours, and malignant ovarian tumours after platinum/cyclophosphamide chemotherapy. Br. J. Cancer 66, 930-936. <https://doi.org/10.1038/bjc.1992.388>
42. van der Zee, A. G., Hollema, H., Suurmeijer, A. J., Krans, M., Sluiter, W. J., Willemse, P. H., Aalders, J. G., de Vries, E. G. (1995) Value of P-glycoprotein, glutathione S-transferase π, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J. Clin. Oncol. 13, 70-78. <https://doi.org/10.1200/JCO.1995.13.1.70>
front cover

ISSN 0015-5500 (Print) ISSN 2533-7602 (Online)

Open access journal

Submissions

Archive